- Home
- NAVI vs TNGX Comparison
NAVI vs TNGX Comparison
Compare NAVI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- TNGX
- Stock Information
- Founded
- NAVI 1973
- TNGX 2014
- Country
- NAVI United States
- TNGX United States
- Employees
- NAVI N/A
- TNGX N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- TNGX Health Care
- Exchange
- NAVI Nasdaq
- TNGX Nasdaq
- Market Cap
- NAVI 1.1B
- TNGX 1.0B
- IPO Year
- NAVI N/A
- TNGX N/A
- Fundamental
- Price
- NAVI $11.44
- TNGX $7.87
- Analyst Decision
- NAVI Hold
- TNGX Strong Buy
- Analyst Count
- NAVI 7
- TNGX 6
- Target Price
- NAVI $14.14
- TNGX $10.80
- AVG Volume (30 Days)
- NAVI 725.8K
- TNGX 4.5M
- Earning Date
- NAVI 10-29-2025
- TNGX 11-04-2025
- Dividend Yield
- NAVI 5.30%
- TNGX N/A
- EPS Growth
- NAVI N/A
- TNGX N/A
- EPS
- NAVI N/A
- TNGX N/A
- Revenue
- NAVI $443,000,000.00
- TNGX $66,501,000.00
- Revenue This Year
- NAVI N/A
- TNGX $20.41
- Revenue Next Year
- NAVI $1.57
- TNGX N/A
- P/E Ratio
- NAVI N/A
- TNGX N/A
- Revenue Growth
- NAVI N/A
- TNGX 53.29
- 52 Week Low
- NAVI $10.53
- TNGX $1.03
- 52 Week High
- NAVI $16.07
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- NAVI 36.01
- TNGX 49.06
- Support Level
- NAVI $11.47
- TNGX $7.49
- Resistance Level
- NAVI $12.33
- TNGX $8.35
- Average True Range (ATR)
- NAVI 0.39
- TNGX 0.64
- MACD
- NAVI -0.01
- TNGX -0.03
- Stochastic Oscillator
- NAVI 2.46
- TNGX 37.59
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.